PROTHROMPLEX TOTAL 600 IU / 20 ML POWDER AND SOLVENT FOR INJECTABLE SOLUTION

2. What you need to know before you start using Prothromplex Total

Do not use Prothromplex Total

• if you are allergic to clotting factors or to any of the other components of this medicine (listed in section 6).
• if heparin has caused or is suspected to have caused a decrease in platelets, the cells responsible for blood clotting (heparin-induced thrombocytopenia).

Warnings and precautions

Traceability

Each time you are administered a dose of Prothromplex Total, it is recommended to record the name and batch number of the product to maintain control of the batches used.

Consult your doctor before starting to use Prothromplex Total

• since there is a rare possibility that you may develop a severe, sudden allergic reaction (anaphylactic reaction) to Prothromplex Total because such allergic reactions have been reported.

You can find detailed information on the first symptoms of this type of allergic reaction in section 4 "Possible side effects"

• if you have an acquired deficiency of vitamin K-dependent clotting factors.

This acquired deficiency may be caused by treatment with medications that neutralize blood clotting through vitamin K inhibition. In this case, Prothromplex Total should only be used when rapid correction of prothrombin complex levels is necessary, such as in cases of severe bleeding or emergency surgery. In other cases, it is sufficient to reduce the dose of the vitamin K antagonist or administer vitamin K.

• if you are taking medications to inhibit blood clotting (vitamin K antagonists). You may have a tendency to form blood clots that can be increased with the administration of human prothrombin complex concentrate.

• if you have a congenital deficiencyof specific clotting factors dependent on vitamin K, a product with the specific factor should be used if available.

• if you are being treated with human prothrombin complex concentrate, especially if you have received it repeatedly, as blood clots (thrombosis) and embolism may occur.

• if you belong to any of the following patient groups, due to the possibility of blood clots:

• patients with coronary heart disease or who have suffered a heart attack
• patients with liver disease
• pre- or post-operative patients
• newborns
• patients at risk of thromboembolic complications or disseminated intravascular coagulation (DIC)

In all these situations, your doctor will carefully evaluate the benefits of treatment with Prothromplex Total against the possible risks of these complications.

Viral safety

When administering medications derived from human plasma or blood, certain measures must be taken to prevent infections from being transmitted to patients.

Such measures include:

• careful selection of donors to exclude those at risk of being carriers of infectious diseases,
• analysis of specific infection markers in individual donations and plasma pools,
• inclusion of stages in the manufacturing process to eliminate/inactivate viruses.

Despite this, when administering medications derived from human blood or plasma, the possibility of transmitting infectious agents cannot be entirely excluded. This also applies to emerging or unknown viruses or other types of infections.

These measures are considered effective against enveloped viruses such as human immunodeficiency virus (HIV), hepatitis B virus, and hepatitis C virus, and against the non-enveloped hepatitis A virus. The measures taken may have limited value against other non-enveloped viruses such as parvovirus B19. Parvovirus B19 infection can be severe for a pregnant woman (fetal infection) and for individuals with a depressed immune system or patients with certain types of anemia (e.g., sickle cell disease or hemolytic anemia).

It is possible that your doctor may recommend vaccination against hepatitis A and hepatitis B if you are regularly or repeatedly administered human prothrombin complex concentrates derived from human plasma.

It is strongly recommended that, each time you are administered a dose of Prothromplex Total, you record the name of the medicine and batch number administered in order to maintain a record of the batches used.

Children and adolescents

The safety and efficacy of using Prothromplex Total in patients under 18 years of age have not been established in clinical trials.

Other medicines and Prothromplex Total

Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.

Tell your doctor if you are taking medications to inhibit blood clotting (vitamin K antagonists). You may have a tendency to form blood clots that can be increased with the administration of human prothrombin complex concentrate.

Interference with biological tests

When performing heparin-sensitive coagulation tests in patients receiving high doses of human prothrombin complex, the heparin contained in the administered product should be considered.

Pregnancy, breastfeeding, and fertility

If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. Prothromplex Total can be used during pregnancy and breastfeeding only in cases where it is clinically indicated.

No information is available on the effects of Prothromplex Total on fertility.

Driving and using machines

No studies have been performed on the ability to drive and use machines.

Prothromplex Total contains sodium and heparin

This medicine contains 81.7 mg of sodium (main component of cooking/table salt) in each vial. This is equivalent to 4.1% of the maximum recommended daily intake of sodium for an adult.

Heparin can cause allergic reactions and a reduction in blood cell count that can affect the blood clotting system. Patients with a history of heparin-induced allergic reactions should avoid using medications that contain heparin.

3. How to use Prothromplex Total

The start, administration, and supervision of treatment should be performed under the strict supervision of a doctor with experience in the treatment of coagulation disorders.

The dose and duration of treatment with Prothromplex Total will depend on several factors such as body weight, severity of the disease, location, and intensity of bleeding or the need to prevent bleeding in surgical procedures.

Your doctor will calculate the dose according to your specific needs and regularly monitor coagulation and your clinical condition (see section "This information is intended only for healthcare professionals").

Method of administration

Intravenous route.

A doctor should supervise the administration of Prothromplex Total.

After reconstitution with the provided sterile water for injection, Prothromplex Total is administered slowly into a vein (intravenous route). The rate of administration depends on your well-being and should not exceed 2 ml per minute (60 IU/min).

Use in children and adolescents

There are insufficient data to recommend the administration of Prothromplex Total in patients under 18 years of age.

If you use more Prothromplex Total than you should

In case of overdose, the risk of thromboembolic complications or consumption coagulopathy increases.

When high doses of human prothrombin complex concentrates have been administered, myocardial infarction, increased consumption of platelets and clotting factors with elevated clot formation in blood vessels (DIC, consumption coagulopathy), venous thrombosis, and pulmonary embolism have been observed.

If you have any further questions on the use of this medicine, ask your doctor.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

As with all plasma-derived treatments, there is a possibility that you may develop a sudden, severe allergic reaction (anaphylactic reaction). In individual cases, this can range from a severe hypersensitivity reaction to anaphylactic shock.

Therefore, you should be aware of the possible early symptoms of an allergic reaction, such as:

• erythema (redness of the skin)
• rash
• appearance of hives on the skin (urticaria)
• itching anywhere on the body
• swelling of the lips and tongue
• difficulty breathing/dyspnea
• chest tightness
• general malaise
• dizziness
• drop in blood pressure

If you notice one or more of these symptoms, stop the infusion immediately. Call your doctor immediately. Severe symptoms require immediate emergency treatment.

When using human prothrombin complex concentrates (including Prothromplex Total), patients may develop resistance (inhibitors) to one or more clotting factors, resulting in the inactivation of blood clotting factors. The appearance of these inhibitors may manifest as an insufficient response to treatment.

During treatment with human prothrombin complex concentrates, blood clots (thrombi) may form and be carried into the bloodstream (embolism). This can lead to complications such as myocardial infarction, increased consumption of platelets and clotting factors with elevated clot formation in blood vessels (consumption coagulopathy), venous thrombosis, and pulmonary embolism.

The following side effects may affect up to 1 in 10 people using Prothromplex Total:

• formation of blood clots throughout the body (disseminated intravascular coagulation), resistance (inhibitors) to one or more of the prothrombin complex factors (factors II, VII, IX, X)
• severe, sudden allergic reaction (anaphylactic shock), anaphylactic reaction, hypersensitivity, stroke, headache
• myocardial infarction (acute myocardial infarction), heart palpitations (tachycardia)

• arterial thrombosis, venous thrombosis, drop in blood pressure (hypotension), flushing of the skin (rubor)
• blockage of a pulmonary blood vessel by a blood clot (pulmonary embolism),difficulty breathing, shortness of breath (dyspnea), wheezing
• vomiting, feeling sick (nausea)
• rash all over the body (urticaria), skin rash (erythematous rash), itching (pruritus)
• a certain kidney disorder with symptoms such as swelling of the eyelids, face, and lower legs with weight gain as well as loss of protein through the urine (nephrotic syndrome)
• fever (pyrexia).

The following side effects have been observed with other human prothrombin complex concentrates:

• swelling of the face, tongue, and lips (angioedema), skin sensation like burning, tingling, itching, or numbness (paresthesia)
• reaction at the injection site
• lethargy
• restlessness

Reporting of side effects

If you experience any side effects, talk to your doctor, even if they are not listed in this leaflet. You can also report them directly through the Spanish Pharmacovigilance System for Human Use Medicines: www.notificaRAM.es.

By reporting side effects, you can help provide more information on the safety of this medicine.

5. Storage of Prothromplex Total

Store in a refrigerator (between 2°C and 8°C). Do not freeze.

Keep the medicine in the original packaging to protect it from light.

Keep this medicine out of the sight and reach of children.

Do not use the medicine after the expiry date that appears on the packaging after EXP. The expiry date is the last day of the month indicated.

During the validity period, the product can be stored at room temperature (max. 25°C) for a period of up to 6 months. The start and end of storage at room temperature should be noted on the medicine packaging.

After storage at room temperature, Prothromplex Total should not be returned to the refrigerator (2°C to 8°C) and should be discarded if not used within 6 months.

Use the solution immediately after reconstitution.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.

6. Container Content and Additional Information

Composition of Prothromplex Total

Powder:

The active principle is the human prothrombin complex, composed of human coagulation factors II, VII, IX, and X, and protein C.

A vial contains at least 400 UI of co-purified protein C with blood coagulation factors.

The other components are: sodium chloride, sodium citrate dihydrate, sodium heparin (0.2-0.5 UI/UI of factor IX), and antithrombin III 15-30 UI per vial (0.75-1.5 UI/ml).

Solvent: Sterile water for injectable preparations.

Appearance of the Product and Container Content

Powder and solvent for injectable solution.

Prothromplex Total is a white or slightly yellow powder, lyophilized or in the form of a compact dry substance.

After reconstitution, the solution has a pH between 6.5 and 7.5 and an osmolality of not less than 240 mosm/kg. The solution is transparent or slightly opalescent.

The powder and solvent are contained in single-dose glass vials (hydrolytic type I and type II glass, respectively) and sealed with butyl rubber stoppers.

Container Content

1 vial with Prothromplex Total 600 UI in powder

1 vial with 20 ml of sterile water for injectable preparations

According to the specific labeling of the country, the containers may contain the following combinations of devices:

-1 transfer needle, 1 air vent needle, 1 filter needle

-1 disposable syringe, 1 triple set (air vent needle, butterfly needle, and disposable needle), 1 filter needle, 1 transfer needle

-1 disposable syringe, 1 air vent needle, 1 butterfly needle, 1 disposable needle, 1 filter needle, 1 transfer needle

-1 triple set (air vent needle, butterfly needle, and disposable needle), 1 filter needle, 1 transfer needle

-1 transfer needle, 1 filter needle, 1 air vent needle, 1 butterfly needle, 1 disposable needle

-1 transfer needle, 1 filter needle, 1 disposable syringe, 1 air vent needle, 1 twin set (butterfly needle, disposable needle)

Container Size1 x 600 UI

Marketing Authorization Holder and Manufacturer

Marketing Authorization Holder:

Baxalta Innovations GmbH

Industriestrasse 67

1221 Vienna

Austria

Manufacturer:

Takeda Manufacturing Austria AG

Industriestrasse, 67

A-1221 Vienna, Austria

Local Representative:

Takeda Farmacéutica España S.A.

Calle Albacete, 5, 9th floor

Edificio Los Cubos

28027 Madrid

Spain

Tel: +34 91 790 42 22

This Medicinal Product is Authorized in the Member States of the European Economic Area with the Following Names:

Date of the Last Revision of this Prospectus: 10/2024

Detailed and updated information on this medicinal product is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es/

-----------------------------------------------------------------------------------------------------------------------

This information is intended only for healthcare professionals:

Dosage

Only general dosage guidelines are provided, except for the treatment of hemorrhages and perioperative prophylaxis of bleeding during treatment with vitamin K antagonists.

Treatment should be initiated under the supervision of a physician with experience in the treatment of coagulation disorders. The dose and duration of replacement therapy depend on the severity of the disorder, the location and intensity of the hemorrhage, and the patient's clinical condition.

The quantity and frequency of administration should be calculated individually for each patient. The dosing intervals should be adapted to the different circulating half-lives of the various coagulation factors in the prothrombin complex.

Individual dosage requirements can only be identified based on periodic determination of plasma levels of the relevant coagulation factors or global analysis of prothrombin complex levels (e.g., Quick test, INR, prothrombin time) and continuous monitoring of the patient's clinical condition.

In the case of major surgical interventions, precise monitoring of replacement therapy is essential through coagulation analysis (specific assays for specific coagulation factors and/or global tests to measure prothrombin complex levels).

Hemorrhage and Perioperative Prophylaxis of Bleeding during Treatment with Vitamin K Antagonists:

In severe hemorrhages or before undergoing high-risk surgical procedures, normal levels should be achieved (Quick test 100%, INR 1.0).

The following rule applies: 1 UI of factor IX per kg of body weight increases the Quick test value by approximately 1%.

If the administration of Prothromplex Total is based on INR values, the dose will depend on the initial INR value before treatment and the target INR value.

The doses described in the following table should be followed according to the recommendations published by Makris et al 20011.

The correction of vitamin K antagonists that induce a persistent deterioration of hemostasis lasts for approximately 6-8 hours. However, the effects of vitamin K, if administered at the same time, are usually achieved within 4-6 hours. Therefore, it is not necessary to repeat treatment with human prothrombin complex when vitamin K has been administered.

As these recommendations are empirical and recovery and duration of effect may vary, INR monitoring during treatment is mandatory.

1Makris M, Watson HG: The Management of Coumarin-Induced Over-Anticoagulation Br. J. Haematol. 2011; 114:271-280

Treatment of Hemorrhages and Perioperative Prophylaxis of Bleeding in Congenital Deficiency of one of the Vitamin K-Dependent Coagulation Factors, when a Purified Specific Coagulation Factor Product is not Available:

The calculation of the required dose for treatment is based on the empirical data that approximately 1 UI of factor VII or factor IX per kg of body weight increases the plasma activity of factor IX by around 0.015 UI/ml; and 1 UI per kg of body weight of factor VII by around 0.024 UI/ml. One UI of factor II or X per kg of body weight increases the plasma activity of factor II or X by around 0.021 UI/ml2

2Ostermann H, Haertel S, Knaub S, Kalina U, Jung K, Pabinger I. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers. Thromb Haemost. 2007;98(4):790-797

The dose of a specific factor administered is expressed in International Units (UI), which are related to the current WHO standard for each factor. The plasma activity of a specific coagulation factor is expressed either as a percentage (relative to normal plasma) or in International Units (relative to the international standard for the specific coagulation factor).

One International Unit (UI) of coagulation factor activity is equivalent to the amount contained in 1 ml of normal human plasma.

The required dose is determined using the following formula:

For example, the calculation of the required dose of factor X is based on the empirical data that 1 International Unit (UI) of factor X per kg of body weight increases the plasma activity of factor X by around 0.017 UI/ml. The required dose is determined using the following formula:

Required Units = body weight (kg) x desired increase in factor X (UI/ml) x 60

where 60 (ml/kg) is the reciprocal of the estimated recovery.

If the individual recovery is known, this value should be used in the calculation.

Pediatric Population

The safety and efficacy of using Prothromplex Total in the pediatric population have not been established in Baxter's clinical trials.

Interaction with Other Medicinal Products and Other Forms of Interaction

If high doses of Prothromplex Total are administered, the heparin contained in the product should be taken into account when performing coagulation analyses sensitive to heparin.

Incompatibilities

This medicinal product should not be mixed with other medicinal products, except with the solvent provided.

As with all coagulation factor medicines, the efficacy and tolerance of the medicine may be affected if mixed with other medicines. It is recommended to flush a common venous access with isotonic saline solution before and after administration of Prothromplex Total.

Special Precautions for Disposal and Other Handling

Only the reconstitution equipment provided should be used for reconstitution.

Prothromplex Total should be reconstituted immediately before administration. The solution should be used immediately after (the solution does not contain preservatives).

The solution is transparent or slightly opalescent. The reconstituted product should be visually inspected before administration to verify the absence of foreign particles or discoloration. Do not use cloudy or precipitated solutions.

Reconstitution of Powder for Injectable Solution:

Use an aseptic technique!

1. Warm the vial containing the solvent (sterile water for injectable preparations), without opening, to room temperature (max. 37°C).
2. Remove the protectors from the vial of concentrate and the vial of solvent (Fig. A) and disinfect the corresponding rubber stoppers.
3. Remove the protector from one end of the included transfer needle, twisting and pulling, and insert the needle through the rubber stopper of the vial of solvent. (Fig. B and C).
4. Remove the protector from the other end of the transfer needle, taking care not to touch the exposed end.
5. Invert the vial of solvent over the vial of powder and insert the free end of the transfer needle through the rubber stopper of the vial of powder (Fig. D). The solvent will be drawn into the vial of powder by vacuum action.
6. Disconnect the two vials by removing the transfer needle along with the vial of solvent from the vial of powder (Fig. E). Gently shake the vial of concentrate to accelerate dissolution.
7. Once the powder is completely dissolved, insert the included air vent needle (Fig. F) and any possible foam will disappear. Remove the air vent needle.

Injection/Infusion:

The reconstituted product should always be visually inspected before administration to verify the absence of foreign particles or discoloration.

Use an aseptic technique!

1. Remove the protector from the included filter needle, twisting and pulling, and place the needle on a sterile disposable syringe. Draw the solution into the syringe (Fig. G).
2. Separate the filter needle from the syringe and slowly administer the solution intravenously (maximum injection/infusion rate: 2 ml/min).

After administration, discard all opened needles along with the syringe and/or administration equipment in the product packaging to avoid putting others at risk.

Disposal of unused medicinal products and all materials that have come into contact with them should be carried out in accordance with local regulations.

Document each administration of Prothromplex Total in the patient's medical record, using the provided self-adhesive label.